The Lung Institute’s Treatment Guidelines for Bronchiectasis Include Cellular Therapy

Bronchiectasis treatment guidelines are designed to help patients manage the symptoms of this chronic obstructive lung condition, which causes airway inflammation and breathing difficulties. Traditionally, the mainstay of bronchiectasis treatment has been antibiotic therapy used in conjunction with mucus-clearing devices. For some patients, this approach can effectively control the chronic bacterial infections that can result from excess mucus buildup. However, for very severe symptoms that do not respond to antibiotic treatment, lung surgery may be considered.

At the Lung Institute, our bronchiectasis treatment guidelines include cellular therapy, an innovative, nonsurgical option. Our physicians have gained worldwide recognition for the successful application of innovative blood-based cellular therapies in treating chronic lung conditions, including bronchiectasis. At our state-of-the-art facilities, we offer minimally invasive outpatient procedures designed to help our patients breathe easier and achieve a better quality of life.

Of course, our bronchiectasis treatment guidelines are highly individualized based on a number of unique factors. For instance, prior to recommending a specific treatment approach for a patient, we consider his or her answers to a number of questions, including:

  • When was he or she diagnosed with bronchiectasis?
  • What is the nature of his or her symptoms (i.e., severity of breathing difficulties, frequency of infections)?
  • Which medications has he or she tried to control the symptoms, and what were the results?
  • Does he or she use supplemental oxygen?
  • Does he or she smoke?
  • Does he or she have any other health concerns?

By harvesting cells that occur naturally within a patient’s own blood and reintroducing them intravenously, the Lung Institute offers an alternative therapy that provides a new source of hope for many patients who previously believed they were out of options. By taking advantage of the natural anti-inflammatory properties of cells, our treatments have shown significant progress in treating chronic pulmonary conditions with minimal side effects.

For more details on our bronchiectasis treatment guidelines and the potential effects of cellular therapy on pulmonary function improvement, contact the Lung Institute today at 888-745-6697.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.